Literature DB >> 32269727

Changed hemodynamics in acute vasoreactivity testing: prognostic predictors in chronic thromboembolic pulmonary hypertension.

Yan-Zhe Yu1,2, Ping Yuan3, Yi-Lan Yang3, Yuan-Yuan Sun3, Qin-Hua Zhao3, Lan Wang3, Rong Jiang3, Wen-Hui Wu3, Jing He3, Jing-Hong Dai1, Yuan Li3, Bigyan Pudasaini4, Jin-Ling Li3, Su-Gang Gong3, Wei-Ping Xie5, Jin-Ming Liu3.   

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is similar to pulmonary arterial hypertension (PAH) in its pathogenesis. Changed hemodynamic parameters in acute vasoreactivity testing (AVT) have proved to be prognostic predictors of PAH. We wanted to determine whether these changed indices also impacted the prognosis of CTEPH. Data was retrieved for 86 CTEPH patients who underwent right heart catheterization (RHC) with AVT at Shanghai Pulmonary Hospital from 2009 to 2018 and following up for 20 ± 15 months for event. Cox proportional hazards models were performed to determine the predictors of independent event-free survival. Receiver operating characteristic curve was plotted to determine the cut-off value of independent parameters in CTEPH. Kaplan-Meier method and log-rank test were used to perform the Survival analyses. Forty seven patients had an event. Many hemodynamic indices improved after AVT. The event-free group had better mean right atrial pressure, mean pulmonary arterial pressure, pulmonary vascular resistance (PVR) and oxygen saturation of mixed venous blood (SvO2) both at baseline and after AVT. The event-free group also showed higher cardiac output (CO) and cardiac index (CI) after AVT. Among the changed hemodynamic parameters during the AVT, ΔCO, ΔCO/baseline CO, ΔCI, ΔCI/baseline CI and ΔPVR/baseline PVR were significantly higher in the event-free group. Foremost, ΔPVR/baseline PVR, PVR after AVT and baseline SvO2 were independent predictors for event-free survival. Patients with SvO2 ≥ 61.65% at baseline or PVR < 8.09 WU after AVT or ΔPVR/baseline PVR ≥ 0.054 had significantly better survival. Hemodynamic indices both at baseline and after AVT as well as the changes in these indices reflected the severity of CTEPH. Baseline SvO2, PVR after AVT, and ΔPVR/baseline PVR could be used as independent predictors to estimate the outcomes of CTEPH patients. AJTR
Copyright © 2020.

Entities:  

Keywords:  Chronic thromboembolic pulmonary hypertension; acute vasoreactivity testing; event-free survival; oxygen saturation of mixed venous blood; pulmonary vascular resistance; right heart catheterization

Year:  2020        PMID: 32269727      PMCID: PMC7137036     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  44 in total

1.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Respir J       Date:  2015-08-29       Impact factor: 16.671

Review 2.  Pulmonary endarterectomy: part I. Pathophysiology, clinical manifestations, and diagnostic evaluation of chronic thromboembolic pulmonary hypertension.

Authors:  Dalia A Banks; Gert Victor D Pretorius; Kim M Kerr; Gerard R Manecke
Journal:  Semin Cardiothorac Vasc Anesth       Date:  2014-06-22

3.  Survival in pulmonary hypertension in Spain: insights from the Spanish registry.

Authors:  Pilar Escribano-Subias; Isabel Blanco; Manuel López-Meseguer; Carmen Jimenez Lopez-Guarch; Antonio Roman; Pilar Morales; María Jesús Castillo-Palma; Javier Segovia; Miguel A Gómez-Sanchez; Joan Albert Barberà
Journal:  Eur Respir J       Date:  2012-02-23       Impact factor: 16.671

4.  Acute responses to inhalation of Iloprost in patients with pulmonary hypertension.

Authors:  Hong-Liang Zhang; Zhi-Hong Liu; Yong Wang; Chang-Ming Xiong; Xin-Hai Ni; Jian-Guo He; Qin Luo; Zhi-Hui Zhao; Qing Zhao; Xing-Guo Sun
Journal:  Chin Med J (Engl)       Date:  2012-08       Impact factor: 2.628

5.  Effect of different pharmacologic agents to reverse severe pulmonary hypertension among end-stage heart failure patients.

Authors:  J Torres Macho; J F Delgado Jimenez; J Sanz Salvo; A Gonzalez Mansilla; V Sanchez Sanchez; S Gamez Diez; P Escribano Subias; C Saenz de la Calzada
Journal:  Transplant Proc       Date:  2009 Jul-Aug       Impact factor: 1.066

6.  Chronic Thromboembolic Pulmonary Hypertension: Experience from a Single Center in Mexico.

Authors:  Nadine Al-Naamani; Gaudalupe Espitia H; Hugo Velazquez-Moreno; Benjamin Macuil-Chazaro; Arturo Serrano-Lopez; Ricardo S Vega-Barrientos; Nicholas S Hill; Ioana R Preston
Journal:  Lung       Date:  2016-01-09       Impact factor: 2.584

7.  Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension.

Authors:  Hiroki Mizoguchi; Aiko Ogawa; Mitsuru Munemasa; Hiroshi Mikouchi; Hiroshi Ito; Hiromi Matsubara
Journal:  Circ Cardiovasc Interv       Date:  2012-11-27       Impact factor: 6.546

Review 8.  Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension.

Authors:  Nobuhiro Tanabe; Toshihiko Sugiura; Koichiro Tatsumi
Journal:  Respir Investig       Date:  2013-04-30

9.  Sex-specific cardiopulmonary exercise testing indices related to hemodynamics in idiopathic pulmonary arterial hypertension.

Authors:  Ping Yuan; Tian-Xiang Chen; Bigyan Pudasaini; Jie Zhang; Jian Guo; Si-Jin Zhang; Lan Wang; Qin-Hua Zhao; Su-Gang Gong; Rong Jiang; Wen-Hui Wu; Jing He; Jin-Ming Liu; Qing-Hua Hu
Journal:  Ther Adv Respir Dis       Date:  2017-01-02       Impact factor: 4.031

10.  Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth.

Authors:  Keyur Donda; Ronald Zambrano; Younghye Moon; Justin Percival; Ruben Vaidya; Fredrick Dapaah-Siakwan; Shihua Luo; Matthew R Duncan; Yong Bao; Luqing Wang; Ling Qin; Merline Benny; Karen Young; Shu Wu
Journal:  PLoS One       Date:  2018-07-10       Impact factor: 3.240

View more
  2 in total

1.  Acute vasoreactivity testing predicts outcome of idiopathic pulmonary arterial hypertension patients with a negative acute response.

Authors:  Yuanyuan Sun; Yuan Li; Xiangrui Meng; Rong Jiang; Qinhua Zhao; Lan Wang; Lingzi Shi; Cijun Luo; Hongling Qiu; Wenhui Wu; Jinling Li; Jing He; Jinming Liu; Ping Yuan; Sugang Gong
Journal:  Ann Transl Med       Date:  2020-12

2.  Soluble ST2 in serum predicts the prognosis of idiopathic pulmonary fibrosis: a retrospective study.

Authors:  Yan-Zhe Yu; Xian-Hua Gui; Min Yu; Wen Huang; Li-Yao Peng; Jing-Hong Dai; Qing-Qing Xu; Ting-Ting Zhao; Wei-Ping Xie; Yong-Long Xiao; Ping Yuan; Yan Li
Journal:  Ann Transl Med       Date:  2022-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.